Premium
Monoclonal antibodies against doxorubicin
Author(s) -
Balsari Andrea,
Alzani Rachele,
Parrello Daniele,
Morelli Daniele,
Tagliabue Elda,
Gianni Luca,
Isetta Anna Maria,
Menard Sylvie,
Colnaghi Maria Ines,
Ghione Mario
Publication year - 1988
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910420528
Subject(s) - monoclonal antibody , doxorubicin , medicine , antibody , monoclonal , immunology , chemotherapy
Hybridomas which secrete monoclonal antibodies (MAbs) reacting with doxorubicin (DXR), a widely used anthracycline cytotoxic antibiotic, have been obtained by fusing NSO/P 3 mouse myeloma cells with spleen cells from BALB/c mice immunized with DXR‐BSA conjugate. The best producer among the several clones obtained was expanded and the secreted MAb (MAD2) purified and characterized. MAD2 cross‐reacts to varying degrees with anthracycline compounds such as some DXR analogues and derivatives, but does not recognize anthracene and anthraquinone structures, with the exception of weakly reacting Mitoxantrone. MAD2 and the panel of MAbs which are at present being purified may become a tool for studying the relevance of different domains of the anthracyclin molecule in terms of biologic activity.